Overview

Bioequivalence Study for Acarbose / Metformin FDC

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Acarbose
Metformin